Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMRN block of 1.1 million shares just went off
Per Yhoo finance, about 14% of the AMRN float is short as of February 15th.
AMRN, reminder that there are two presentations today
http://finance.yahoo.com/news/Amarin-to-Present-at-Two-prnews-3046344838.html?x=0&.v=1
Joseph Zakrzewski, Executive Chairman and Chief Executive Officer, is scheduled to present at the CITI 2011 Global Healthcare Conference on Wednesday, March 2, 2011 at 2:00 pm ET. This conference will be held at the Hilton New York City. A live audio webcast of the presentation will be available at http://www.veracast.com/webcasts/citigroup/healthcare2011/75211419.cfm.
John Thero, President, is scheduled to present at the RBC Capital Markets' Healthcare Conference on Wednesday, March 2, 2011 at 4:35 pm ET. This conference will be held at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be available at http://www.wsw.com/webcast/rbc129/amrn.
AMRN--Interesting, I see on the wires this morning that Soffinova LP sold 363,000 shares at 8.13 on February 25, 2011
AMRN is drifting for 2 reasons
(1) a bunch of people bought on the CEO remarks in January and are bagholders are are exiting out
(2) there is an absence of catalysts in the short term until the timeline for the next set of data becomes clearer.
If you look at the volume it is mostly going down. This one is going to take great patience.
AMRN--I do not agree that it has broken all support.
Notice how the whole time it has pulled back volume has been light.
(AMRN 90 day avg daily volume 2.7 million)
If you remember the offering price was 7.60/share, it has good suuport there I believe.
This is going to take patience but it has great potential
The Wonder Of Apple’s Tablet
http://www.techcrunch.com/2009/12/25/apples-tablet-islate/
ETFC--Every member of the board of directors of E*TRADE Financial (ETFC), including the company's acting chief executive officer, bought stock yesterday as shares of the beleaguered online brokerage and bank rose to their best levels in seven weeks. In total, ten insiders at the $1.9B market cap company took down an aggregate of 474.7K shares, or about $1.93M in stock. The buys were the first on the open market for seven of the insiders and come with ETFC in the beginning stages of a turnaround plan aimed at repairing the damage from the mortgage meltdown.
STP you mean, looks like big news for AKNS
Doug kass's 20 surprises of 2008 list
http://www.seekingalpha.com/article/58749-possible-improbables
ASTI went on this
http://www.sciam.com/article.cfm?id=a-solar-grand-plan
Though the article failed to mention ASTI's (CIGS) copper indium gallium diselenide it is a thin film, and in lab testing it has the highest efficiency of the thin film category at 19.5% accordding to ASTI's website, the next fastest is cadmium telluride or CdTe which is produced by First Solar which was specifically named in the article.
Crisis may make 1929 look a 'walk in the park'
http://www.telegraph.co.uk/money/main.jhtml;jsessionid=YMI3JMHWNF5HNQFIQMFCFFOAVCBQYIV0?xml=/money/2007/12/23/cccrisis123.xml
Too dire for me but something to be aware of
Here is the telegraph article on this
http://www.telegraph.co.uk/money/main.jhtml?xml=/money/2007/11/12/cnbric112.xml
"As home loan market tightens, mounting credit card debt could spur new crisis"
It's not just a problem for the working poor, credit counselors say. Many middle- and upper-class households have come to view credit card debt as a reality of modern life.
"The psychology about carrying credit card debt has changed. What used to be a shame is just an additional way to buy stuff, and stuff is the operative word here," said Catherine Williams, vice president of financial literacy at Consumer Credit Counseling Service of Greater Chicago.
Freda Price, a divorced mother of two in Bethlehem, Pa., is trying to get her credit card debt under control. Five years ago, Price had a $49,000 mortgage and no significant credit card balances. But she now is struggling with $100,000 in mortgage and credit card balances because she has refinanced and used the cards to pay for attorneys in a long-running dispute over child custody with her ex-husband.
Price is close to hitting the maximum borrowing limit on her four credit cards, which are consuming about $300 a month in minimum payments. She finds herself charging gas and groceries on the cards, which she doesn't like.
"The sad thing is I never had any of this debt before," she said. "I have to pay the minimum because I can't afford much more."
Price's credit cards also are preventing her from saving for retirement. She is contributing only 1 percent to her 401(k) plan even though her insurance company employer matches up to 3 percent.
"I'm just between a rock and a hard place. I pack my lunch. I get the newspaper at the house. We don't go out to eat. We don't do much of anything," said Price, 51. "I was always very thrifty, but I don't know where else to cut."
http://www.chicagotribune.com/business/chi-sun_crunch0826aug26,0,2958622,print.story
SE has had a bunch of insider buys lately
http://www.form4oracle.com/company?cik=0001373835&ticker=SE
PCR super numbers
PCR Perini Corporation reports Q1 EPS $0.84 vs Reuters consensus $0.58 (45.92)
Company reports revenues of $987.4M vs Reuters $947.2M. The increase in revenues is primarily due to an increased volume of work in the hospitality and gaming market as a result of the new contract awards received in the latter half of 2005 which are now well into the construction phase. The backlog of uncompleted construction work at 31-Mar was $8.6B, up from the $8.5B backlog reported at 31-Dec-06. Guides full year revenues to $4.0-4.2B vs Reuters $3.98B and previous range of $3.8-4.0B. Guides next year EPS to $2.40-2.60 vs Reuters $2.58 and previous range of $2.00-$2.20.
VII has been a real disappointment, the chart really borke down there.
Alas.
LXU LSB Industries pops to highs of the day (18.30 +0.32) :
LXU's conf call going on; hearing that EPS was much better than reported due to conversion of preferred shares. Most cos would have backed that out, but LXU did not, so numbers would have been better than reported.
Look at the super volume yesterday and today on this chart
CROX wow
CROX Crocs reports Q1 EPS $0.61 vs Reuters consensus $0.49 (57.41)
Company reports revenues of $142.0M vs Reuters $113.9M. Guides Q2 EPS to $0.80-0.85 vs Reuters $0.63; guides revenues to $180-190M vs Reuters $135.6M. Guides full year EPS to $2.90-2.95 vs Reuters $2.42; guides revenues to $670-680M vs Reuters $540.1M. CROX also declared a 2-1 stock split, payable 14-Jun.
DNDN--The News is nervous shorts before the weekend
Home-loan guru says foreclosures could rise more
The sharp decline of the subprime housing market offering high-cost mortgages hasn't hit bottom yet, the head of home mortgage buyer Freddie Mac said Friday.
The number of home buyers starting such loans peaked last year, and interest rates for those buyers are due to rise in the next few years, which could cause foreclosures to rise more, Richard F. Syron said in an interview with The Associated Press.
"The mortgages written in 2006 in the subprime market are probably the most troublesome," said Syron, chairman and chief executive of Freddie Mac. "They haven't hit the reset point yet on interest rates."
Subprime mortgages that became increasingly popular in recent years typically draw borrowers in with a low "teaser" interest rate that can later spike upward.
I have been listening to analysts and other leaders say the housing market has bottomed for the last 9 months. It is refreshing to have someone give us the truth--KSH.
Read it all here:
http://www.tennessean.com/apps/pbcs.dll/article?AID=/20070428/BUSINESS01/704280316/1044
Anyone watching DEEP ipo today?
SYNL great eps report, hope some of you are in
SYNL Synalloy reports Q1 EPS $0.56 vs year-ago $0.11 (32.72)
Company reports revenues of $44.4M vs year-ago $36.2M. Management remains confident in the potential success of its fire retardant products over the balance of 2007. SYNL is anticipating an increase in revenues from these products to begin in the second quarter and grow to significant volumes steadily throughout the year. The company believes that the Specialty Chemicals Segment should produce improved results in the last 3 quarters of 2007. Piping systems' backlog should continue to provide a much higher level of sales and profits for piping systems over the balance of 2007 compared to the same period last year.
Iran begins making nuclear fuel in underground uranium enrichment plant, IAEA Paper - Reuters
buying back SLP on the pullback
looking for 17-20 later this year
SYNL speaking of great ibd ratings
99 99 98 A+ C A-
page b7 of today's ibd
SYNL on pace for a possible record volume day
Zeev, our prayers and thoughts are with you, thanks for sharing.
SMCI can't get any traction, new ipo today
GOT seeing good accumulation
FUL beats and raises
FUL H.B. Fuller reports Q1 EPS $0.34 vs Reuters consensus $0.29 (25.53)
Company reports revenues of $351.8M vs Reuters $358.6M. Company increases f07 EPS guidance to $1.65-1.75 vs Reuters $1.64. Previous guidance was $1.58-1.68. Average selling prices contributed 4.1% and volume declines reduced growth by 10.3% year-over-year.
good chart
GOOG Google initiated Buy/Aggressive at AG Edwards (463.62)
Target is $550.
GOOG LG Electronics to add Google services to phones - Reuters.com (463.62 )
Reuters.com reports South Korea's LG Electronic and Internet search giant Google on Wednesday said they would pre-install Google services on LG mobile phones. LG handsets with Google products and services, such as Google Maps, Gmail and Blogger, will be shipped to North America, Europe and Asia starting in 2Q07, the cos said. LG plans to release at least 10 new handset models with the Google products in 2007 and continue offering them for the next few years. The two cos will jointly mkt the handsets.
BWLD pretty breakout
FOXH is 50 dma breakout on above average daily volume (at current pace anyhow)
OSIR boom
Osiris Therapeutics Inc.’s easy-to- administer stem cell treatment helped patients recover after a heart attack and eased their symptoms in a study.
The cells were given intravenously to patients who had a heart attack within the past 10 days, researchers said. The hearts of those who got the cells pumped 25 percent more efficiently both three months and six months after treatment, according to research presented today at a science meeting.
The study, using adult cells gathered from bone marrow, is the first to transfer stem cells from donors to heart patients. Since an IV line delivers the cells, rather than a complex heart procedure, “they could be given at a community hospital'’ rather than an academic center, said Marc Penn, director of the Bakken Heart Brain Institute at the Cleveland Clinic.
“It’s very exciting, perhaps a sea-changing trial for the field,'’ said Penn, who was not involved with the study and has no relationship with Osiris. Because the cells don’t come from the patients themselves, they can be made in large batches “offering the chance for an off-the-shelf product,'’ he said.
http://www.bloomberg.com/apps/news?pid=20601087&sid=a_YZBRXSFiKs&refer=home
OSIR just got a very positive mentioned on a bloomberg tv segment on stem cells companies
had no idea that was coming
FCSX trying to turn back up
SYNL accumulation continues
high ibd ratings of 99 and 98
will be very high in IBD 100 some day
OSIR presenting new data sunday
Adam Feuerstein of realmoney.com is watching eagerly for it:
http://www.thestreet.com/p/_rms/dps/cc/20070322/columnistconversation1.html#entryId10346081
Osiris Therapeutics (OSIR) is up 15% today on heavy volume because the company will be releasing clinical data Sunday on a new stem cell treatment for heart attack patients.
I am embargoed by the company until Sunday so I cannot disclose the data here (You'll need to wait for Sunday to read my take.)But i can point you to an article in the MIT Technology Review from yesterday that talks in general about the Osiris clinical trial. It's this article that has traders buzzing and the OSIR stock up, I think. You know that momentum investors love anything regarding stem cells.
One thing I will say about this study is that it's early stage and a lot more work will need to be done.